Nothing said here yet.
to join the conversation.
| Robertson Stephen P.Chief Legal Officer | Sell | 11,939 | $190.4K | Thu, Sep 10 |
| Robertson Stephen P.Chief Legal Officer | Sell | 20,975 | $355.9K | Fri, Aug 21 |
Aurinia (AUPH) delivered earnings and revenue surprises of +15.00% and -4.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
EDMONTON, Alberta (AP) — EDMONTON, Alberta (AP) — Aurinia Pharmaceuticals Inc. (AUPH) on Friday reported third-quarter net income of $31.
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On August 6, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and six months ended June 30, and the numbers showed a company converting revenue growth into a much bigger jump in profit.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute.
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals stock has delivered a 74.2% return over the past three years, and the broader valuation checks currently lean toward the shares being on the cheap side rather than fully priced.
Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS.
Aurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?